These findings have important clinical implications, as measuring baseline activity of the COX-2/PGE2 pathway in tumours pan-cancer type could help identify patients most likely to benefit from the addition of a COX-2 inhibitor to chemoimmunotherapy regimens. The gene discussed is PTGS2; the disease is neoplasm.